Core Viewpoint - Southbound funds have reduced their holdings in Universal Medical (02666.HK) by 801,000 shares on January 9, 2026, indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - In the last five trading days, southbound funds have reduced their holdings for four days, with a total net reduction of 12,016,500 shares [1] - In the last twenty trading days, there were 13 days of net increases in holdings, totaling 1,486,000 shares [1] - As of now, southbound funds hold 448 million shares of Universal Medical, accounting for 22.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - Universal Medical Group Co., Ltd. (formerly known as Universal Medical Financial and Technical Consulting Services Co., Ltd.) operates in the healthcare sector in China [2] - The company operates through two main segments: financial services, which include direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services; and healthcare services, which encompass hospital operation management, medical equipment import and export trade, and medical digital technology services [2] - The company's primary operations are conducted within mainland China [2]

（来源：工人日报） 本报讯（记者刘友婷）"以前来复诊，从香港过关到福田口岸后，无论坐公交还是地铁，都要多次换 乘，路上要花近1个小时，对我们来说确实不方便。"香港的高先生是香港大学深圳医院的"老朋友"，也 是香港长者医疗券计划的受益者，1月5日，他坐上了首班接驳巴士，连连感叹"太方便了"。记者了解 到，为进一步推动跨境医疗服务衔接，港大深圳医院与深圳巴士集团合作，正式开通"福田口岸—港大 深圳医院"接驳巴士专线。这是港大深圳医院探索深港医疗融合的又一成果。 港大深圳医院院长张文智表示，这条巴士专线不是简单的交通补充，而是让患者的就医路从"可及"升级 为"便捷"，推动跨境医疗从"能就医"向"便捷就医"跨越。 来自香港的钟先生和家人经常到港大深圳医院就诊。此前，他从福田口岸前往医院，需要搭乘的士，或 转乘两次地铁。当天体验接驳巴士专线后，他表示，专线不仅实现直达，出行时间更加可控，交通成本 也明显降低，"既可以投现金，也可以刷深港互通卡，很方便"。 除了交通更便捷，在多年实践基础上， 港大深圳医院已构建起一套全方位、多层次、高度融合的跨境 医疗服务体系。 在语言服务方面，医院组建了专业的粤语服务团队，确保从预约、 ...

人民财讯1月9日电，据金域医学（603882）消息，1月9日，中山大学附属第三医院(简称"中山三院")、 金域医学和联通数智医疗联合打造的中山三院人工智能医生正式问世。据悉，这是基于真实住院病例与 完整诊疗路径进行推理的人工智能医生，在助力临床医生在提升诊疗效率的同时，也能推动更多高水平 医疗智慧和资源下沉到基层医疗一线。 ...

专题：美国12月非农略低于预期 美国劳工部周五公布，12月经季节性调整后新增就业人数50000人，失业率降至4.4%。 这一新增就业人数低于接受调查的经济学家预期的73000人，也弱于11月经修正后的新增56000人。 12月的就业报告是几个月来首份能清晰反映劳动力市场状况的报告，此前创纪录时长的政府停摆导致政 府机构停止数据收集工作长达六周，并推迟了许多主要经济指标的发布。 周五的报告为2025年画上了句号，在这一年里，劳动力需求明显放缓，公司收紧了招聘。2025年，就业 创造步履维艰，薪资增长降温，失业率上升。2025年的大部分就业创造都集中在两个行业：教育和医疗 服务。 2025年对美国经济来说是不寻常的一年。美国总统特朗普1月份上任后，其政府采取行动大幅削减联邦 政府雇员数量，并限制进入美国和在美国工作的移民数量。白宫还在春季宣布对进口商品征收全面关 税，扰乱了金融市场。 但尽管美国就业市场一直疲软，经济一直在稳步增长，虽然第一季度出现短暂波折。在有数据可查的最 近一个季度（即第三季度），得益于强劲的消费者支出和对人工智能（AI）领域的稳健商业投资，国 内生产总值（GDP）创下两年来最快增速。作为衡量 ...

证券日报网讯1月9日，塞力医疗（603716）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东总户数66905户。 ...

Core Insights - The China Clinical Case Results Database has developed into a significant platform for evaluating clinical talent and promoting quality medical practices, with over 122,000 standardized case reports from more than 5,000 medical institutions by the end of 2025, and a total readership exceeding 31 million [3][4] Group 1 - The database aims to establish a national, standardized, and high-quality platform to convert clinical experiences into academic achievements that can be widely shared and scientifically evaluated, moving away from traditional metrics like the number of publications to focus on the value of outcomes [3] - The database provides a wealth of practical teaching cases that help medical professionals, especially grassroots and young doctors, to accumulate clinical experience more rapidly and enhance their diagnostic capabilities [4] - Users of the database come from over 80 countries and regions, indicating its growth from a domestic platform to one with international visibility and influence [4] Group 2 - The Chinese Medical Association plans to enhance the database by improving the peer review system to encourage more medical professionals to summarize and refine clinical experiences while ensuring quality [4] - There is a focus on expanding the application of the database in professional title evaluations for medical staff, allowing them to dedicate more time to patient care [4] - The initiative aims to extend the database's role from title evaluations to encompass the entire career lifecycle of medical professionals, thereby maximizing its impact [4]

Group 1 - The core viewpoint of the article is to introduce the CSI Technology Advantage Growth 50 Strategy Index, which aims to provide investors with multi-factor strategy investment targets based on the technology sector [1] - The index selects stocks from the technology industry based on factors such as growth, innovation, value, low volatility, and quality, focusing on companies with high trading volumes [1] - The index is rebalanced quarterly, with a maximum weight of 10% and a minimum of 0.1% for individual stocks [2] Group 2 - The top ten constituent stocks of the index include leading companies in various technology sectors, with a combined weight of 30.93% for the top ten stocks [2][3] - The index is heavily weighted towards large-cap stocks, with 31 constituents having a market capitalization exceeding 100 billion yuan [3][4] - The index shows a significant focus on the electronics industry, while also maintaining weights in telecommunications, computing, and pharmaceuticals [3] Group 3 - The article presents the performance of various factors within the sample space, indicating that growth, consensus expectations, and low volatility factors exhibit strong stock selection effects [20] - The analysis includes a comparison of the Technology 50 Strategy Index with other technology and innovation indices, highlighting its historical performance and annual returns [20][22] - The Technology 50 Strategy Index has a cumulative return of 97.26% over the backtesting period, ranking third among six technology indices [23] Group 4 - The expected revenue growth for the Technology 50 Strategy Index in 2026 is projected at 33.65%, outperforming other technology indices [25][29] - The index employs 11 factors for stock selection, providing a comprehensive evaluation compared to other indices that focus on fewer factors [31][32] - The article emphasizes the importance of analyst consensus expectations as a forward-looking indicator for company performance [31]

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services (BDMS) to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Market Overview - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025. The specialty health check segment is the fastest-growing part, indicating strong demand for advanced and targeted screening solutions [1] Strategic Partnership - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer, to enhance early disease detection services across nearly 60 hospitals within the N Health network [2] Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3] Innovation in Testing - The new home test kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into one component, significantly reducing contamination and user error risks [3][4] Accessibility and Consumer Focus - The company aims to distribute these test kits through modern trade channels and pharmacies across Thailand, aligning with evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4]

从高价收购到1元抛售，跨界医疗与光伏的梦想在残酷现实面前碎成一地。"1元清仓大甩卖"，这样的标 签不仅出现在夜市地摊，更出现在一家A股上市公司的资产转让公告中。 2025年12月30日，永和智控宣布拟以1元价格第六次挂牌转让旗下光伏公司泰兴普乐51%股权及债权， 距离首次挂牌价3049万元，降幅接近100%。 这不是孤例。过去一年内，永和智控多次挂牌转让旗下肿瘤医院股权，其中达州医科肿瘤医院和西安医 科肿瘤医院的挂牌价也一度降至1元，却依然无人接盘。 市场无情地回应了这场跨界野心——三年来公司累计亏损4.79亿元，资产负债率从上市初的12.8%飙升 至73.24%，实控人曹德莅三次筹划易主均以失败告终。 01 跨界"大跃进"：医疗光伏双折戟，资产1元甩卖仍难出手 永和智控的跨界之路始于2019年，随着新任实控人曹德莅入主，这家以阀门管件为主业的公司开始激进 转型。公司相继收购多家肿瘤医院，包括达州、昆明、凉山、西安等地项目，总耗资超2.4亿元，这些 医院在被收购时已处于亏损状态。 2022年，公司又通过增资控股泰兴普乐切入光伏赛道，试图抓住新能源风口。跨界并未带来预期的增 长。昆明医科肿瘤医院2025年前七个 ...

每经AI快讯，有投资者在投资者互动平台提问：请问公司在三胎和婴童领域有哪些相关业务？ 新里程（002219.SZ）1月9日在投资者互动平台表示，投资者您好，公司旗下绵阳爱贝尔妇产医院及兰 考第一医院下辖兰考妇儿医院是专业的妇儿医院，其他多家综合医院设有妇科、产科、儿科等专业科 室。兰考妇儿医院为国家爱婴医院、河南省新生儿重症救护网络成员单位。绵阳爱贝尔妇产医院是四川 省爱婴医院，开设了产科、妇科、新生儿科等科室。感谢您的关注。 （记者 曾健辉） ...